PrEP, or pre-exposure prophylaxis, is an HIV prevention method prescribed to HIV-negative adults and adolescents who are at high risk for getting HIV through sex or injection drug use. It allows those who don’t already have HIV to take a daily pill to reduce their risk of getting HIV if exposed to the virus. Studies have shown that PrEP reduces the risk of getting HIV from sex by about 99% when taken daily, and that it is highly effective for preventing HIV if it is used as prescribed. Among people who inject drugs, PrEP reduces the risk of getting HIV by at least 74% when taken daily. PrEP is much less effective when it is not taken consistently.
Currently, there are only two FDA-approved medications for PrEP:
- emtricitabine and tenofovir disoproxil fumarate, sold under the brand name Truvada®
- emtricitabine and tenofovir alafenamide, sold under the brand name Descovy®